Mike Poole

Dr. Poole currently serves as an advisor for Neumora Therapeutics and for Gates Ventures. He also serves on the Board of Directors for MMS and for several biotechnology companies, both public and venture-funded. 

Previously, Dr. Poole led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation. Prior to joining the Gates Foundation, Dr. Poole served as Vice President and head of Neuroscience Innovation at AstraZeneca. He also served as Chief Medical Officer for Link Medicine and Hypnion, and was Vice President of Neuroscience Development at Wyeth and Pfizer.

At MMS, Dr. Poole provides guidance on the design, conduct, and reporting of global phase 2-4 clinical trials, the implementation of clinical development plans, and global regulatory filings. He has supported a wide range of indications from analgesia, pain, neurology, Alzheimer’s Disease, psychiatry, infectious disease and more.

Dr. Poole earned his undergraduate degree at the University of California, Berkeley and his medical degree from the UC San Diego School of Medicine. He is board certified in internal medicine, having trained at Strong Memorial Hospital at the University of Rochester. He also is board-certified in adult neurology, completing his post-graduate training in neurology at the University of Michigan.

In his free time, he can often be found sailing the waters of Puget Sound, enjoying the incredible scenery.

Suggested For You

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth